All In Biotech

NDA 019855 · Aurobindo Pharma USA

Elimite

Permethrin · Topical · Pyrethroid

Last checked: Nov 20, 2026Latest source record: Feb 12, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Aug 25, 1989

Approved uses

2

Original approval plus efficacy supplements

Registered trials

43

18 Phase 3, 1 recruiting

FAERS reports

1,358

690 serious, 58 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 4, 2026.

INDICATIONS AND USAGE: Permethrin Cream, 5% is indicated for the treatment of infestation with Sarcoptes scabiei (scabies).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 5, 1993 Supplement 1 · Efficacy
  • Aug 25, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
  • ELIMITE · PERMETHRIN 5% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Permethrin" as an intervention, any sponsor and status, largest first.

All 43 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
20059
20067
20074
20085
200917
201028
201121
201229
201324
201433
201540
201684
201792
2018137
2019155
2020141
2021134
202280
202374
202498
202598
202637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 277 on PubMed

Sponsor: Aurobindo Pharma USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.